150 N. RADNOR CHESTER ROAD, RADNOR, PA
Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
Other Events
Earnings Release
Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
News
Reports First Quarter 2025 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Mineralys Therapeutics Reveals Key Data from Advance-HTN Trial at ACC.25
Q1
FY 2023
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
SEC Staff Correspondence